A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy
Abstract
Purpose:
Multiparametric magnetic resonance imaging and biopsy based molecular tests such as the 17-gene Oncotype DX® Genomic Prostate Score™ assay are increasingly performed to improve risk stratification in men with clinically localized prostate cancer. The prostate score assay was previously shown to be a significant independent predictor of adverse pathology findings at radical prostatectomy in men diagnosed by systematic biopsies only. Therefore, we investigated the ability of the prostate score assay to predict adverse pathology findings in the setting of magnetic resonance imaging guided prostate biopsy.
Materials and Methods:
We identified men diagnosed with NCCN® (National Comprehensive Cancer Network®) very low, low or intermediate risk prostate cancer who underwent simultaneous multiparametric magnetic resonance imaging fusion targeted and systematic prostate biopsy with subsequent radical prostatectomy within 6 months. Prostate score assay testing was performed on biopsy tissue with the highest Gleason score. The primary outcome of the study was adverse pathology findings, defined as Gleason score 4 + 3 or greater disease and/or pT3+ at radical prostatectomy. Independent predictors of adverse pathology findings were determined in a multivariable model to adjust for clinical parameters.
Results:
A total of 134 men were eligible for primary analysis. On univariable analysis the UCLA score, magnetic resonance imaging, prostate score assay results and biopsy Gleason score were significant predictors of adverse pathology findings. After multivariable adjustment prostate score assay values remained a significant predictor of adverse pathology results (prostate score assay per 20 U OR 3.28, 95% CI 1.74–6.62, p <0.001). A wide and overlapping distribution of prostate score assay results was seen across PI-RADS® (Prostate Imaging Reporting and Data System) version 2 scores.
Conclusions:
The prostate score assay result is an independent predictor of adverse pathology findings in patients who were diagnosed with very low, low or intermediate risk prostate cancer in the setting of multiparametric magnetic resonance imaging fusion prostate biopsy. This assay can be useful as an independent technology or an adjunct technology to multiparametric magnetic resonance imaging to individualize risk stratification of low and intermediate risk prostate cancer.
References
- 1 : On risk estimation versus risk stratification in early prostate cancer. PLoS Med2016; 13: e1002100. Google Scholar
- 2 : Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology2012; 80: 1075. Google Scholar
- 3 : Who bears the greatest burden of aggressive treatment of indolent prostate cancer?. Am J Med2015; 128: 609. Google Scholar
- 4 : Genomic predictors of outcome in prostate cancer. Eur Urol2015; 68: 1033. Google Scholar
- 5 : Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol2015; 68: 1045. Google Scholar
- 6 : The role of magnetic resonance imaging in delineating clinically significant prostate cancer. Urology2014; 83: 369. Google Scholar
- 7 : Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol2015; 67: 569. Google Scholar
- 8 : Characteristics of detected and missed prostate cancer foci on 3-T multiparametric MRI using an endorectal coil correlated with whole-mount thin-section histopathology. AJR Am J Roentgenol2015; 205: W87. Google Scholar
- 9 : Prostate cancer: interobserver agreement and accuracy with the revised prostate imaging reporting and data system at multiparametric MR imaging. Radiology2015; 277: 741. Google Scholar
- 10 : Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol2016; 70: 233. Google Scholar
- 11 : Magnetic resonance imaging underestimation of prostate cancer geometry: use of patient specific molds to correlate images with whole mount pathology. J Urol2017; 197: 320. Link, Google Scholar
- 12 : Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. J Urol2014; 192: 1367. Link, Google Scholar
- 13 : A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol2015; 68: 123. Google Scholar
- 14 : A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol2014; 66: 550. Google Scholar
- 15 : Clinical validation of a 17-gene genomic prostate score (GPS) assay as a predictor of distant metastases in men with prostate cancer (PCa) treated with radical prostatectomy (RP) in a community setting. Eur Urol2017; 16: e618. Google Scholar
- 16 : Utility of the Oncotype DX® prostate cancer assay in clinical practice for treatment selection in men newly diagnosed with prostate cancer: a retrospective chart review analysis. Urol Pract2015; 2: 343. Link, Google Scholar
- 17 : Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). PLoS One2017; 12: e0185535. Google Scholar
- 18 : REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol2005; 2: 416. Google Scholar
- 19 : Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol2013; 189: 86. Link, Google Scholar
- 20 : PI-RADS Prostate Imaging-Reporting and Data System: 2015, version 2. Eur Urol2016; 69: 16. Google Scholar
- 21 : Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies. Cancer2016; 122: 884. Google Scholar
- 22 : Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol2012; 61: 1019. Google Scholar
- 23 : The incremental role of magnetic resonance imaging for prostate cancer staging before radical prostatectomy. Eur Urol2017; 71: 701. Google Scholar
- 24 : Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol2011; 185: 869. Link, Google Scholar
- 25 : Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urol Oncol2016; 34: 415e1. Google Scholar
- 26 : Negative predictive value of multiparametric MRI for prostate cancer detection: outcome of 5-year follow-up in men with negative findings on initial MRI studies. Eur J Radiol2014; 83: 1740. Google Scholar
- 27 : Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol2014; 66: 22. Google Scholar
